Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

196 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Assessment of Patient-Derived Xenograft Growth and Antitumor Activity: The NCI PDXNet Consensus Recommendations.
Meric-Bernstam F, Lloyd MW, Koc S, Evrard YA, McShane LM, Lewis MT, Evans KW, Li D, Rubinstein LV, Welm AL, Dean DA, Srivastava A, Grover JW, Ha MJ, Chen H, Huang X, Varadarajan K, Wang J, Roth JA, Welm BE, Govindan R, Ding L, Kaochar S, Mitsiades N, Carvajal-Carmona LG, Herlyn M, Davies MA, Shapiro GI, Fields RC, Trevino JG, Harrell JC, Doroshow JH, Chuang JH, Moscow JA. Meric-Bernstam F, et al. Among authors: mcshane lm. Mol Cancer Ther. 2024 Apr 20. doi: 10.1158/1535-7163.MCT-23-0471. Online ahead of print. Mol Cancer Ther. 2024. PMID: 38641411
National Cancer Institute Combination Therapy Platform Trial with Molecular Analysis for Therapy Choice (ComboMATCH).
Meric-Bernstam F, Ford JM, O'Dwyer PJ, Shapiro GI, McShane LM, Freidlin B, O'Cearbhaill RE, George S, Glade-Bender J, Lyman GH, Tricoli JV, Patton D, Hamilton SR, Gray RJ, Hawkins DS, Ramineni B, Flaherty KT, Grivas P, Yap TA, Berlin J, Doroshow JH, Harris LN, Moscow JA. Meric-Bernstam F, et al. Among authors: mcshane lm. Clin Cancer Res. 2023 Apr 14;29(8):1412-1422. doi: 10.1158/1078-0432.CCR-22-3334. Clin Cancer Res. 2023. PMID: 36662819 Free PMC article. Clinical Trial.
The New NCI Precision Medicine Trials.
Harris LN, Blanke CD, Erba HP, Ford JM, Gray RJ, LeBlanc ML, Hu-Lieskovan S, Litzow MR, Luger SM, Meric-Bernstam F, O'Dwyer PJ, Othus MKD, Politi K, Shepherd LE, Allegra CJ, Chen HX, Ivy SP, Korde LA, Little RF, McShane LM, Moscow JA, Patton DR, Thurin M, Yee LM, Doroshow JH. Harris LN, et al. Among authors: mcshane lm. Clin Cancer Res. 2023 Dec 1;29(23):4728-4732. doi: 10.1158/1078-0432.CCR-23-0917. Clin Cancer Res. 2023. PMID: 37531248 Free PMC article.
Phase II Study of Osimertinib in Patients With Epidermal Growth Factor Receptor Mutations: Results From the NCI-MATCH ECOG-ACRIN (EAY131) Trial Subprotocol E.
Chen MF, Song Z, Yu HA, Sequist LV, Lovly CM, Mitchell EP, Moscow JA, Gray RJ, Wang V, McShane LM, Rubinstein LV, Patton DR, Williams PM, Hamilton SR, Umemura Y, Tricoli JV, Conley BA, Arteaga CL, Harris LN, O'Dwyer PJ, Chen AP, Flaherty KT. Chen MF, et al. Among authors: mcshane lm. JCO Precis Oncol. 2024 Apr;8:e2300454. doi: 10.1200/PO.23.00454. JCO Precis Oncol. 2024. PMID: 38591867 Clinical Trial.
The NCI-MATCH trial: lessons for precision oncology.
O'Dwyer PJ, Gray RJ, Flaherty KT, Chen AP, Li S, Wang V, McShane LM, Patton DR, Tricoli JV, Williams PM, Iafrate AJ, Sklar J, Mitchell EP, Takebe N, Sims DJ, Coffey B, Fu T, Routbort M, Rubinstein LV, Little RF, Arteaga CL, Marinucci D, Hamilton SR, Conley BA, Harris LN, Doroshow JH. O'Dwyer PJ, et al. Among authors: mcshane lm. Nat Med. 2023 Jun;29(6):1349-1357. doi: 10.1038/s41591-023-02379-4. Epub 2023 Jun 15. Nat Med. 2023. PMID: 37322121 Review.
Phase II Study of Afatinib in Patients With Tumors With Human Epidermal Growth Factor Receptor 2-Activating Mutations: Results From the National Cancer Institute-Molecular Analysis for Therapy Choice ECOG-ACRIN Trial (EAY131) Subprotocol EAY131-B.
Bedard PL, Li S, Wisinski KB, Yang ES, Limaye SA, Mitchell EP, Zwiebel JA, Moscow JA, Gray RJ, Wang V, McShane LM, Rubinstein LV, Patton DR, Williams PM, Hamilton SR, Conley BA, Arteaga CL, Harris LN, O'Dwyer PJ, Chen AP, Flaherty KT. Bedard PL, et al. Among authors: mcshane lm. JCO Precis Oncol. 2022 Jul;6:e2200165. doi: 10.1200/PO.22.00165. JCO Precis Oncol. 2022. PMID: 35939768 Free PMC article. Clinical Trial.
Trametinib in Patients With NF1-, GNAQ-, or GNA11-Mutant Tumors: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocols S1 and S2.
Wisinski KB, Flamand Y, Wilson MA, Luke JJ, Tawbi HA, Hong F, Mitchell EP, Zwiebel JA, Chen H, Gray RJ, Li S, McShane LM, Rubinstein LV, Patton D, Williams PM, Hamilton SR, Behrens RJ, Pennington KP, Conley BA, Arteaga CL, Harris LN, O'Dwyer PJ, Chen AP, Flaherty KT. Wisinski KB, et al. Among authors: mcshane lm. JCO Precis Oncol. 2023 Apr;7:e2200421. doi: 10.1200/PO.22.00421. JCO Precis Oncol. 2023. PMID: 37053535 Free PMC article.
196 results